If you have been reading about Angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
=== Theories on amputation === In medieval Europe, amputation was done on limbs as a last resort when the limb could not be saved. For limbs that were dead or decaying, surgeons categorized them into two main categories: hot fire and cold fire. Hot fire (also called Gangraena) was the first stage of a decaying limb. A body part with hot fire was hot, swollen, and painful. If not treated, the limb would turn cold. Cold fire (also called Sphacelus) was the late stage of limb death, including death of the bone. Symptoms included loss of feeling, coldness, and black and blue coloring. With time, the fire would spread and eventually kill the patient. Followers of Galen considered hot and cold fire to be based on the humors and an imbalance of hot, wet, dry, and cold in the body. Followers of Paracelsus believed that hot and cold fire were a result of Mercury, sulfur, and salt. While different surgeons drew from different medical theories of the time, they also used their own experiences to determine the root cause of the fires. There was often debate on whether a particular patient had cold or hot fire, which led to disagreements on treatment methods. Treatment for hot fire often included burning or cutting out damaged flesh. If the symptoms were mild enough, the skin could sometimes be regrown. Treatment for cold fire included removing the dead flesh and likely amputation.
=== Security and authentication === Security packaging can include tamper-evident closures, security printing, holograms, digital watermarks, RFID tags, unique serial numbers, covert markers, and forensic authentication features. These systems help identify counterfeiting, diversion, unauthorised opening, product substitution, and manipulation of the package. Authentication systems may combine visible, covert, forensic, and digital elements. Scan data from serialised codes can also help identify unusual copying or distribution patterns.
=== Single-atom wave propagation === Electron waves in graphene propagate within a single-atom layer, making them sensitive to the proximity of other materials such as high-κ dielectrics, superconductors, and ferromagnets.
Channa amari Dey et al., 2019 — likely a synonym of C. brunnea Channa amphibeus (McClelland, 1845) (Borna snakehead) Channa andrao Britz, 2013 Channa ara (Deraniyagala, 1945) Channa argus (Cantor, 1842) (northern snakehead) Channa aristonei Praveenraj, Thackeray, Singh, Uma, Moulitharan & Mukhim, 2020 Channa asiatica (Linnaeus, 1758) (small snakehead) Channa aurantimaculata Musikasinthorn, 2000 (orange-spotted snakehead) Channa aurantipectoralis Lalhlimpuia, Lalronunga & Lalramliana, 2016 Channa auroflammea Adamson, Britz and S. Lieng, 2019 Channa aurolineata (F. Day, 1870) Channa bankanensis (Bleeker, 1853) Channa baramensis (Steindachner, 1901) Channa barca (F. Hamilton, 1822) (barca snakehead) Channa bipuli Praveenraj, Uma, Moulitharan & Bleher, 2018 Channa bleheri Vierke, 1991 (rainbow snakehead) Channa brahmacharyi Chakraborty, Yardi & Mukherjee, 2020 Channa brunnea Praveenraj, Uma, Moulitharan & Kannan, 2019 Channa burmanica B. L. Chaudhuri, 1919 Channa coccinea Britz, H. H. Tan & Rüber, 2024 Channa cyanospilos (Bleeker, 1853) Channa diplogramma (F. Day, 1865) (Malabar snakehead) Channa gachua (F. Hamilton, 1822) (dwarf snakehead) Channa harcourtbutleri (Annandale, 1918) (Burmese snakehead) Channa hoaluensis Nguyen, 2011 Channa kelaartii (Günther, 1861) Channa limbata (Cuvier, 1831) Channa lipor Praveenraj, Uma, Moulitharan & Singh, 2019 Channa longistomata (Nguyen & Nguyen, 2012) Channa lucius (G. Cuvier, 1831) (forest snakehead) Channa maculata (Lacépède, 1801) (blotched snakehead) Channa marulioides (Bleeker, 1851) (emperor snakehead) Channa marulius (F.
Sources: en.wikipedia.org
In Somaliland, the Isaaq Sultanate was established in 1750. The Isaaq Sultanate was a Somali kingdom that ruled parts of the Horn of Africa during the 18th and 19th centuries. It spanned the territories of the Isaaq clan, descendants of the Banu Hashim clan, in modern-day Somaliland and Ethiopia. The sultanate was governed by the Rer Guled branch established by the first sultan, Sultan Guled Abdi, of the Eidagale clan. According to oral tradition, prior to the Guled dynasty the Isaaq clan-family were ruled by a dynasty of the Tolje'lo branch starting from, descendants of Ahmed nicknamed Tol Je'lo, the eldest son of Sheikh Ishaaq's Harari wife. There were eight Tolje'lo rulers in total, starting with Boqor Harun (Somali: Boqor Haaruun) who ruled the Isaaq Sultanate for centuries starting from the 13th century. The last Tolje'lo ruler Garad Dhuh Barar (Somali: Dhuux Baraar) was overthrown by a coalition of Isaaq clans. The once strong Tolje'lo clan were scattered and took refuge amongst the Habr Awal with whom they still mostly live. In the late 19th century, after the Berlin Conference of 1884, European powers began the Scramble for Africa. In that year, a British protectorate was declared over part of Somalia, on the African coast opposite South Yemen. Initially, this region was under the control of the Indian Office, and so administered as part of the Indian Empire; in 1898 it was transferred to control by London.
A group of South American species formerly placed in the genus Datura are now placed in the distinct genus Brugmansia (Brugmansia differs from Datura in that it is woody (the species being shrubs or small trees) and has indehiscent fruits.) The solanaceous tribe Datureae, to which Datura and Brugmansia belong, has recently acquired a new, monotypic genus Trompettia J. Dupin, featuring the species Trompettia cardenasiana, which had hitherto been misclassified as belonging to the genus Iochroma. Datura specialists Ulrike Preissel and Hans-Georg Preissel accept only nine species of Datura, but Kew's Plants of the World Online lists the following 14 (out of which its related The Plant List does not include D. arenicola, D. lanosa and D. pruinosa as accepted spp.):
==== Substance dependence ==== Modafinil has been studied as a potential treatment for stimulant dependence and cocaine addiction, but clinical trials have failed to show that it helps reduce drug use or maintain abstinence; 2024 reviews found it ineffective for amphetamine-type stimulant use disorder, methamphetamine use disorder, and cocaine dependence.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.